 |
6 Diseases |  |
3 Trials |
|
3 Trials |  |
89 News |  |
| 12» |
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
P2 data, Journal: Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. (Pubmed Central) - Sep 3, 2024
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder. At 3 years, 88% of the patients remained free of cystectomy.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal, Machine learning: Rapid, antibiotic incubation-free determination of tuberculosis drug resistance using machine learning and Raman spectroscopy. (Pubmed Central) - Jun 11, 2024
At 3 years, 88% of the patients remained free of cystectomy. We collect few-to-single-cell Raman spectra from over 25,000 cells of the Mtb complex strain Bacillus Calmette-Gu
- 18F-FDG PET/CT Mapping Identifies Spleen as Dominant Site for Blood Glucose Uptake in BCG-Treated Patients with Type 1 Diabetes (Poster Hall (West A4-B2); 891) - May 20, 2024 - Abstract #ADA2024ADA_2896;
These findings suggest that the spleen, triggered by BCG vaccinations, assumes a critical role in systemic glucose regulation in the absence of a functional pancreas. This data fits with surgical data wherein splenectomy can cause diabetes in patients due to glucose dysregulation.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Letter to the Editor Regarding "The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result". (Pubmed Central) - Feb 6, 2024
This data fits with surgical data wherein splenectomy can cause diabetes in patients due to glucose dysregulation. No abstract available
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. (Pubmed Central) - Dec 5, 2023
Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Randomized Double Blinded Phase II and Phase III Testing of the BCG Vaccine for COVID-19 and Platform Infectious Disease Protection in the United States (Concourse C & D) - Nov 8, 2023 - Abstract #VaccinesRD2023Vaccines_RD_60;
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Phase classification: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Oct 3, 2023
P2, N=20, Completed, Sponsor: Massachusetts General Hospital
Further investigation with a prospective trial is imperative. Phase classification: P1 --> P2
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Peripheral and Central Nervous System Immune Effects of Bacillus Calmette-Gu (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2486;
A further study including subjects with MCI and AD is ongoing. Our interventional studies with BCG begin to explore whether this strategy of retraining the neuroimmune axis can prevent and/or treat AD.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Airway T (Pubmed Central) - Jun 19, 2023
Blood immune features were less predictive of protection. We
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer. (Pubmed Central) - May 23, 2023
In this study, BCG vaccine was associated with a significantly lower rate and risk of ADRD in a cohort of patients with bladder cancer when accounting for death as a competing event. However, the risk differences varied with time.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
New P2 trial: Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years (clinicaltrials.gov) - May 19, 2023
P2, N=100, Recruiting, Sponsor: Massachusetts General Hospital
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation, Imfinzi (durvalumab) / AstraZeneca
P1 data, Journal, Combination therapy: A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (Pubmed Central) - May 15, 2023
D combined with intravesical BCG or EBRT proved feasible and safe in BCG-unresponsive NMIBC patients. Encouraging preliminary efficacy justifies further study of combination therapy approaches.
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
BCG Clinical Trial Programs in Advanced Type 1 Diabetes - 2023 Update (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1768;
Global studies on the effects of BCG on the immune system show that the impact of multi-dose vaccination in MS and T1D is optimized by at least 2 years of follow up and that the effects appear durable without further treatment in both MS and T1D to 5+ years. BCG vaccine therapy may provide a safe and affordable medical intervention in individuals with longstanding autoimmunity.
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
18F-FDG PET/CT Mapping of Functional Microbial Niches to Understand Host Glucose Regulation after BCG Vaccinations (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_641;
Findings from human and murine studies support the spleen as the niche for the BCG vaccine's functional improvement of metabolism. The spleen is significant because it is a lymphoid organ massive enough to explain BCG's systemic benefit of lowering blood sugar to near normal levels in T1D.
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Lowered HbA1c in Individuals with Long-term Type 1 Diabetes Undergoing BCG Bladder Cancer Therapy (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_147;
The data suggests that high-dose intravesical BCG therapy may contribute towards a drop in HbA1c values in T1D, but not T2D. This is consistent with earlier interventional trials of the BCG vaccine in longstanding T1D.
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Clinical, Observational data, Journal: Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies. (Pubmed Central) - Jan 21, 2023
Our ecological analysis of global data suggests a role for neonatal BCG in the prevention of T1D and, to a lesser extent, T2D. Randomized clinical trials are needed to confirm these findings.
- | Adstiladrin (nadofaragene firadenovec) / Ferring, Keytruda (pembrolizumab) / Merck (MSD), bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal, HEOR: Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer. (Pubmed Central) - Dec 19, 2022
Pembrolizumab, though not cost-effective in our base-case analysis, is an important alternative in this population with an unmet medical need. Comparative trials of these treatments are warranted to better estimate cost-effectiveness.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Journal, Next-generation sequencing: Optimizing DNA Extraction from Pediatric Stool for Diagnosis of Tuberculosis and Use in Next-Generation Sequencing Applications. (Pubmed Central) - Dec 9, 2022
Human stool samples were spiked with various concentrations of Mycobacterium bovis bacillus Calmette-Guérin (BCG), and DNA was extracted from the samples using four different DNA extraction kits...IMPORTANCE This is the first study to compare Mycobacterium tuberculosis DNA extraction techniques from pediatric stool samples for use with sequencing technologies. It provides an important starting point for other researchers to isolate quality DNA for this purpose to further the field and to continue to optimize protocols and approaches.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal, IO biomarker: BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes. (Pubmed Central) - Nov 18, 2022
The TCR sequence is not modified through recombination, ruling out a qualitative defect. These findings support an underlying density defect in the TCR affecting TCR signal strength in T1D.
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Clinical, Journal: Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. (Pubmed Central) - Sep 24, 2022
P2
There were no BCG-related systemic adverse events. BCG's broad-based infection protection suggests that it may provide platform protection against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other pathogens.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Trial completion, Trial completion date, Trial primary completion date: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Aug 24, 2022
P1, N=20, Completed, Sponsor: Massachusetts General Hospital
BCG's broad-based infection protection suggests that it may provide platform protection against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other pathogens. Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Apr 2022 | Trial primary completion date: Aug 2022 --> Apr 2022
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Retrospective data, Review, Journal: Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. (Pubmed Central) - Aug 22, 2022
Our results suggest that BCG vaccination at birth is effective at preventing tuberculosis in young children but is ineffective in adolescents and adults. Immunoprotection therefore needs to be boosted in older populations.
- bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
No difference in prevalence of TB infection among infants in two Southern African cohorts by in utero HIV exposure status () - May 12, 2022 - Abstract #AIDS2022AIDS_2551;
TB infection prevalence was similar between two Southern African infant cohorts regardless of fetal HIV exposure status, contrary to previous reports where overall prevalence was higher in infants. Studies with larger cohorts are needed to confirm these findings.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Enrollment closed: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Apr 11, 2022
P1, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Studies with larger cohorts are needed to confirm these findings. Recruiting --> Active, not recruiting
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Enrollment change, Trial withdrawal: Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia (clinicaltrials.gov) - Apr 6, 2022
P2, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting N=300 --> 0 | Suspended --> Withdrawn
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Enrollment open: Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes (clinicaltrials.gov) - Apr 4, 2022
P2, N=150, Recruiting, Sponsor: Massachusetts General Hospital
N=300 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Recruiting
- | Mycobacterium bovis BCG / Murdoch Children's Research Institute, bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: BCG vaccine's off-target effects on allergic, inflammatory and autoimmune diseases: Worth another shot? (Pubmed Central) - Mar 4, 2022
Not yet recruiting --> Recruiting No abstract available
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Single-cell transcriptomic profiles reveal changes associated with BCG-induced trained immunity and protective effects in circulating monocytes. (Pubmed Central) - Feb 15, 2022
Other modules exhibit increased coordination, including several humanin nuclear isoforms that we confirm induce trained immunity in vitro. Our results link in vivo BCG administration to single-cell transcriptomic changes, validated in human genetics experiments, and highlight genes that are putatively responsible for non-specific protective effects of BCG.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: The influence of the gut microbiome on BCG-induced trained immunity. (Pubmed Central) - Jan 29, 2022
Roseburia is found to alter both trained immune responses and phenylalanine metabolism, revealing microbes and microbial products that may alter BCG-induced immunity. Together, our findings contribute to the understanding of specific and trained immune responses after BCG vaccination.
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Review, Journal: A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. (Pubmed Central) - Jan 21, 2022
Although we have a better understanding of the biology of bladder cancer, we still have a long way from being able to cure patients with bladder cancer and eliminate morbidity from treatments. Nevertheless, considerable progress has been made since the founding of the Urologic Oncology Journal 25 years ago.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
New P2 trial: Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes (clinicaltrials.gov) - Jan 6, 2022
P2, N=150, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Trial completion date, Trial primary completion date: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Dec 1, 2021
P1, N=20, Recruiting, Sponsor: Massachusetts General Hospital
Nevertheless, considerable progress has been made since the founding of the Urologic Oncology Journal 25 years ago. Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: BCG therapy is associated with long-term, durable induction of Treg signature genes by epigenetic modulation. (Pubmed Central) - Nov 17, 2021
Corresponding mRNA, Treg expansion and clinical improvement supported the significance of the epigenetic DNA changes. Taken together, the findings suggest that BCG has systemic impact on the T cells of the adaptive immune system, and restores immune balance through Treg induction.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Temporal dynamics of intradermal cytokine response to tuberculin in Mycobacterium bovis BCG-vaccinated cattle using sampling microneedles. (Pubmed Central) - Oct 28, 2021
The results reveal an orchestrated and coordinated cytokine and local chemokine response, identified IL-1RA as a potential soluble biomarker of a positive tuberculin skin response, and confirmed the utility of IFN-γ and IP-10 for bTB detection in blood-based assays. Together, the results highlight the utility of SMNs to identify novel biomarkers and provide mechanistic insights on the intradermal cytokine and chemokine responses associated with the tuberculin skin test in BCG-sensitized cattle.
- | Journal: The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer. (Pubmed Central) - Oct 28, 2021
The model is included in ICER's Interactive Modeler, for which a fee is paid to UIC and Touchette. Atlas also received funding from ICER for work on this report.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: evidence for broad based applications. (Pubmed Central) - Oct 15, 2021
Finally, in vivo experiments with the NOD mouse (a T1D model) and obese db/db mice (a T2D model) confirm BCG's blood-sugar-lowering and accelerated glucose metabolism with sufficient dosing. Our results suggest that BCG's benefits for glucose metabolism may be broadly applicable to T1D and T2D, but less to LADA.
- || bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Clinical, Journal: BCGitis of the wrist after intravesical BCG therapy: a case report. (Pubmed Central) - Sep 3, 2021
This case emphasizes the importance of taking into account the patient's medical history. Tuberculosis of the wrist is a rare etiology for septic arthritis; delayed treatment leads to severe complications and functional sequelae.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Trial completion date, Trial primary completion date: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Aug 18, 2021
P1, N=20, Recruiting, Sponsor: Massachusetts General Hospital
Tuberculosis of the wrist is a rare etiology for septic arthritis; delayed treatment leads to severe complications and functional sequelae. Trial completion date: Jul 2021 --> Nov 2021 | Trial primary completion date: Jul 2021 --> Nov 2021
- || cisplatin / Generic mfg.
Review, Journal: Quality Indicators for Bladder Cancer Services: A Collaborative Review. (Pubmed Central) - Jun 28, 2021
We propose a set of QIs for both NMIBC and MIBC based on established clinical guidelines and the available literature. Measurement of these QIs could aid in improvement and benchmarking of optimal care of bladder cancer.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Journal: TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. (Pubmed Central) - Jun 24, 2021
Furthermore, heterologous vaccine effects were updated, including the use of Bacillus Calmette-Guérin (BCG) vaccine as potential treatment for type 1 diabetes. Finally, the workshop also included presentations and discussion on emergent virus and zoonoses, vaccine resilience, building and sustaining confidence in vaccination, approaches to vaccine decision-making, pros and cons of compulsory vaccination, the latest advances in decoding infectious diseases by RNA gene signatures, and the application of big data approaches.
- ||| bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Clinical, Clinical guideline, NCCN guideline, Journal: Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (Pubmed Central) - Jun 9, 2021
Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease...Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Trial suspension: Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia (clinicaltrials.gov) - Jun 1, 2021
P2, N=300, Suspended, Sponsor: Massachusetts General Hospital
Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra. Not yet recruiting --> Suspended
- Instiladrin (nadofaragene firadenovec) / Ferring, bacillus Calmette-Guerin (BCG) /
[VIRTUAL] Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC) () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_427;
NADO and OPOR may provide bladder-sparing therapeutic alternatives for BCG- unresponsive NMIBC patients. Pricing of these drugs will determine whether they are cost effective at commonly accepted thresholds.
- bacillus Calmette-Guerin (BCG) /
[VIRTUAL] Use of the BCG Vaccine as a Platform to Protect from Diverse Infectious Disease: The Data for COVID-19 Infections () - Apr 4, 2021 - Abstract #PEGS2021PEGS_525;
Second the BCG vaccine appears to confer lifelong protection Finally, with >100 years of safety the BCG vaccine could be used in children. The BCG vaccine may be a cost-effective approach for all more even health access to protective medicines.
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Enrollment open: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Mar 3, 2021
P1, N=20, Recruiting, Sponsor: Massachusetts General Hospital
The BCG vaccine may be a cost-effective approach for all more even health access to protective medicines. Not yet recruiting --> Recruiting
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Trial completion date, Trial primary completion date: Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia (clinicaltrials.gov) - Jan 28, 2021
P2, N=300, Not yet recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Enrollment closed, Trial completion date, Trial primary completion date: Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes (clinicaltrials.gov) - Jan 25, 2021
P2, N=150, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Trial completion date: Jul 2023 --> Jul 2027 | Trial primary completion date: Jul 2020 --> Jul 2025 | Recruiting --> Active, not recruiting
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, Trial initiation date: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Nov 18, 2020
P1, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Jul 2023 --> Jul 2027 | Trial primary completion date: Jul 2020 --> Jul 2025 | Recruiting --> Active, not recruiting Initiation date: Aug 2020 --> Nov 2020
- | bacillus Calmette-Guerin (BCG) / Lacocca Family Foundation
Biomarker, New P1 trial: A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (clinicaltrials.gov) - Aug 10, 2020
P1, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
- bacillus Calmette-Guerin (BCG) /
Underlying Lymphoid Glucose Utilization Defects in Type 1 Diabetes Are Corrected by BCG: Implications for Type 2 Diabetes and Development of Quantitative Methods (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_3026;
Despite higher baseline levels of sugar utilization compared to T1D or NDC, BCG-treated T2D lymphocytes are also responsive to BCG, showing larger increases in sugar uptake than NDC lymphocytes. BCG in vitro or in vivo can increase glucose uptake by lymphocytes in both types of diabetes.